[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639253":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":53,"collaborators":32,"id":57,"slug":32,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":32,"enrollmentInfo":66,"targetDuration":32,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":78,"overallStatus":84,"whyStopped":32,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide","EXPERIMENTAL","Participants receive once-weekly subcutaneous semaglutide for 18 months. Semaglutide is initiated at 0.25 mg weekly for 4 weeks and escalated to 0.5 mg weekly thereafter. Participants also receive standard-of-care management and lifestyle modification counseling, including low-fat diet, physical activity, weight management, smoking cessation, and alcohol limitation.",[13],"Drug: Semaglutide",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants receive once-weekly matching placebo (normal saline) subcutaneous injections for 18 months following the same administration schedule as the experimental arm. Participants also receive standard-of-care management and lifestyle modification counseling, including low-fat diet, physical activity, weight management, smoking cessation, and alcohol limitation.",[19],"Drug: Placebo (Normal Saline)",[21,28],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Semaglutide is administered as a once-weekly subcutaneous injection for 18 months. Treatment is initiated at 0.25 mg once weekly for the first 4 weeks and escalated to 0.5 mg once weekly thereafter to improve tolerability.",[9],[26,27],"Ozempic","Wegovy",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo (Normal Saline)","Placebo consists of normal saline administered as a once-weekly subcutaneous injection following the same administration schedule as semaglutide for 18 months. Participants receive 0.25 mg-equivalent injection volume once weekly for the first 4 weeks followed by 0.5 mg-equivalent injection volume once weekly thereafter.",[15],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Dong Wu, Medical Doctor","CONTACT","8618612671010","dongwu@pumc.edu.cn",[40],{"facility":5,"status":32,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Beijing","Beijing Municipality","100730","China",{"type":46,"coordinates":47},"Point",[48,49],116.39723,39.9075,{"lat":49,"lon":48},[52],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","DONG WU","Professor of Gastroenterology","100639253",false,"NCT07617155","GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis","Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial","RECAP-GLP1","Inclusion Criteria\n\n* Age ≥ 18 years old\n* Previous diagnosis of index HTG-AP (defined as AP with serum TG \\>1000 mg\u002FdL or a serum TG level of 500-1000 mg\u002FdL accompanied by chylous serum)36-38\n* Having HTG as the exclusive cause of AP\n* Time from discharge of index HTG-AP to recruitment between 4 weeks to 3 months, without AP-related symptoms between discharge and recruitment\n* Expression of the willingness to comply with lifestyle modification during the study period.\n* Clinically stable at the time of inclusion\n* The ability to understand the trial and completing it, as evaluated by the investigators.\n* Patients who may get pregnant should ensure using contraceptives for 20 months after inclusion Exclusion Criteria\n* History of malignancy in past 5 years\n* History of hypothyroidism, nephrotic syndrome, Cushing's syndrome or AIDS\n* History of chronic pancreatitis or pancreatic neoplasm\n* History of severe cardiovascular and pulmonary diseases, such as heart failure, coronary heart disease and chronic obstructive pulmonary disease.\n* Severe renal deficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n* Severe hepatic deficiency (Child-Pugh Class B or C)\n* Previous pancreatic surgery\n* Recurrent AP due to pancreatic diverticulum\n* Recurrent AP due to known genetic mutations (eg. CFTR)\n* Personal or family history of medullary thyroid carcinoma (MTC)\n* Current or prior diagnosis or suspected diagnosis of multiple endocrine neoplasia type 2 (MEN2)\n* Serious hypersensitivity reaction to semaglutide or any of the excipients in the investigational drug or placebo\n* Pregnancy\n* Breast-feeding","ALL","18 Years",{"count":67,"type":68},396,"ESTIMATED","INTERVENTIONAL",[71],"PHASE4","Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is associated with a high risk of recurrence despite standard lipid-lowering therapy and lifestyle modification. The goal of this clinical trial is to evaluate whether GLP-1 receptor agonist therapy can reduce the recurrence of HTG-AP in adults with a history of HTG-AP and hypertriglyceridemia.\n\nThe main questions this study aims to answer are:\n\n* Whether GLP-1 receptor agonist therapy reduces the recurrence rate of HTG-AP.\n* Whether GLP-1 receptor agonist therapy improves triglyceride control, body weight, and metabolic parameters.\n* Whether GLP-1 receptor agonist therapy is safe and well tolerated in this patient population.\n\nResearchers will compare GLP-1 receptor agonist therapy plus standard care with standard care alone to determine whether GLP-1 receptor agonist therapy provides additional benefit in preventing recurrent HTG-AP.\n\nParticipants will:\n\n* Receive either GLP-1 receptor agonist therapy plus standard care or standard care alone.\n* Undergo regular clinical follow-up visits and laboratory assessments.\n* Receive monitoring of triglyceride levels, recurrence events, metabolic outcomes, and adverse events during the study period.",[74,75,76,77],"Hypertriglyceridemia Induced Acute Pancreatitis","Recurrent Acute Pancreatitis","Pancreatitis Relapsing","Hypertriglyceridemia",[79,80,81,82,83],"hypertriglyceridemia-induced acute pancreatitis","recurrent acute pancreatitis","semaglutide","GLP-1 receptor agonist","pancreatitis prevention","NOT_YET_RECRUITING","2026-05-28",{"date":87,"type":88},"2026-06-01","ACTUAL",{"date":90,"type":68},"2026-09",{"date":92,"type":68},"2028-12",{"name":5,"class":6},1]